BI

Bio Rad Laboratories IncNYSE BIO Stock Report

Last reporting period 30 Sep, 2024

Updated 20 Nov, 2024

Last price

Market cap $B

9.144

Middle

Exchange

XNYS - New York Stock Exchange, Inc

BIO Stock Analysis

BI

Uncovered

Bio Rad Laboratories Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

14/100

Low score

Market cap $B

9.144

Dividend yield

Shares outstanding

29.596 B

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. The company is headquartered in Hercules, California and currently employs 8,200 full-time employees. The firm operates through two segments: Life Science and Clinical Diagnostics. Life Science segment markets and develops, manufactures and markets a portfolio of various products that serves a global customer base. The segment is focused on specific segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology and food safety. Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. Its products address specific niches within the in vitro diagnostics (IVD) test market.

View Section: Eyestock Rating